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Abstract: Prolonged dexamethasone (Dex) administration leads to serious adverse and decrease brain
and heart size, muscular atrophy, hemorrhagic liver, and presence of kidney cysts. Herein, we used an
untargeted proteomic approach using liquid chromatography-tandem mass spectrometry (LC-MS/MS)
for simultaneous identification of changes in proteomes of the major organs in Sprague–Dawley
(SD rats post Dex treatment. The comparative and quantitative proteomic analysis of the brain,
heart, muscle, liver, and kidney tissues revealed differential expression of proteins (n = 190, 193, 39,
230, and 53, respectively) between Dex-treated and control rats. Functional network analysis using
ingenuity pathway analysis (IPA revealed significant differences in regulation of metabolic pathways
within the morphologically changed organs that related to: (i) brain—cell morphology, nervous
system development, and function and neurological disease; (ii) heart—cellular development, cellular
function and maintenance, connective tissue development and function; (iii) skeletal muscle—nucleic
acid metabolism, and small molecule biochemical pathways; (iv) liver—lipid metabolism, small
molecular biochemistry, and nucleic acid metabolism; and (v) kidney—drug metabolism, organism
injury and abnormalities, and renal damage. Our study provides a comprehensive description of the
organ-specific proteomic profilesand differentially altered biochemical pathways, after prolonged
Dex treatement to understand the molecular basis for development of side effects.
Keywords: dexamethasone; label-free proteomics; LC-MS/M; rat tissues; glucocorticoid side effects;
proteomic expression; network pathway
1. Introduction
Dexamethasone (Dex) is an exogenous synthetic glucocorticoid (GC) with potent anti-inflammatory
and immunosuppressive properties, which has made its use in clinics the mainstay for treatment of
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many inflammatory conditions, autoimmune diseases, and allergic reactions [1]. Glucocorticoids are
known to regulate numerous physiological and metabolic processes [2] by genomic and non-genomic
mechanisms [3] mediated through its binding to cytosolic glucocorticoid receptors (GRs). The GRs
belong to a superfamily of ligand-regulated nuclear receptors that are widely expressed in the body
and have gene targets of GRs signaling in a variety of tissues and cell types [4], including liver [5],
adipocytes [6], and myotubes [7]. The presence of these widespread GRs allows the non-specific binding
of Dex that result in the development of potentially harmful side effects that outweigh its benefits. Aside
from this, the complexity of Dex action is increased with respect to its downstream signaling pathways,
which vary differently among different tissues or organs, as well as within the same tissue but present at
different locations. This differential action of Dex within the same organ was related to the differences in
the tissue’s origin as well as to its microenvironment. Administration of Dex is known to preferentially
increase central adiposity but also causes a decrease in the peripheral fat mass. It induces chondrogenesis
of mesenchymal stem cells in the bone marrow while suppressing it in the synovium [8].
Long-term clinical use of Dex is discouraged as it leads to development of tissue-specific glucocorticoid
resistance and serious side effects that include hypertension, diabetes, abdominal obesity and osteoporosis.
The changes in the metabolite pattern in animal models treated with Dex were highlighted in our previous
study that showed presence of hyperglycemia, weight change, osteoporosis, muscle atrophy, hemorrhage
in the lung and liver [9], and kidney cysts [10]. These observed morphological changes might be the result
of Dex-induced perturbations in the proteins related to the different metabolic and biochemical pathways
in the different organs affected by its pharmacokinetics. Identification of this differential regulation of
proteins and their involved pathways in different organs, either due to the direct or non-specific systemic
binding, to the widely expressed GR, will help in furthering our understanding of the molecular actions
of Dex. The morphogenic changes in the different organs, seen in our previous study, and identification of
the cause of these changes will be of interest to explain the effects of prolonged Dex use. Single protein
datasets from individual organs provide only lists of proteins. On the other hand, integration of the
proteins from the different organs, at the same time, will provide a better picture of complete biochemical
changes and protein dynamics taking place within the animals [11].
Proteomic techniques have become the mainstay in providing insights into the mechanisms of
the biological process through characterization of cellular protein composition and functional linkages
between protein molecules. Previous studies have used the proteomic approach to study changes
in different rat tissues only one at a time, such as lens crystallins [12,13], retina [14], bone marrow
mesenchymal stem cells [15], heart [16], and liver [17]. In a recent study, Biancotto et al. [18] identified
proteins altered in bovine liver after Dex treatment by using an untargeted shot-gun proteomics approach
based on tandem mass tags. The untargeted proteomic analysis provides an assessment tool to assess the
metabolism and the adverse effects of the drug, which cannot be evaluated using classical drug assays
that are limited to single molecules or targeted towards single pathways. Comprehensive biochemical
profiling and characterization of these proteome-wide alterations in different tissues will enable us
to understand the complex interacting metabolic events that occur within a cell, its pathophysiology,
and determine signature proteins [19]. Recently, Hinkelbein et al. [20] carried out a simulataneous
proteomic profiling of the rat organs to identify the affected pathways after short-term hypoxia. In the
present study, we used a label-free quantitative proteomics-based liquid chromatography-tandem mass
spectrometry (LC-MS/MS) approach to simultaneously study the unique protein signatures in different
rat tissues after long-term exposure to Dex treatment as a snapshot in time.
2. Results
2.1. Clinical Phenotypes
During the experiment, the Dex-treated rats went through several phenotypic changes such as
reduction in age-dependent body weight by ~20%, elevation in blood glucose and triglyceride (TG)
levels with markedly reduced low-density lipoprotein in comparisonto the control group (p < 0.001),
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as reported previously [10]. During the sacrificing of the animals, distinct morphological changes in
the soft-tissue mass and variation in organ size in the Dex-treated animals were noted [10]. Both the
brain and the heart were determined to be smaller in size, the skeletal muscle showed atrophy, the liver
demonstrated grossly hemorrhagic changes, and cystic changes of the kidney were noted in the
Dex-treated animals as compared to the control group. A triplicate set of samples were taken for
proteomics analysis from the same pool from each organ as detailed in Figure 1.
  
Figure 1. A flow chart of the animal study design and proteomics based liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) experiment. Sprague–Dawley rats were divided into two groups; control 
(n = 10) and Dex (n = 10). After 14 weeks of twice-weekly treatment with Dex, the proteomics profile of 
freshly collected tissue samples from major body organs were studied using shotgun proteomics analysis. 
Figure 1. A flow chart of the animal study design and proteomics based liquid chromatography-tandem
mass spectrometry (LC-MS/MS) experiment. Sprague–Dawley rats were divided into two groups;
control (n = 10) and Dex (n = 10). After 14 weeks of twice-weekly treatment with Dex, the proteomics
profile of freshly collected tissue samples from major body org ns were studied using shotgun
proteomics analysis.
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The protein expression datasets obtained after LC MS/MS mass spectrometric analysis, in samples
from each of the individual organs, were compared by running a principal component analysis (PCA)
analysis. The PCA plots constructed from them showed a clear separation between the control and
Dex-treated samples for the brain, kidney, heart, and muscle samples (Figure 2A) and skeletal muscles
and liver (Figure 2B).
Th  protein xpression dataset  obtained after LC MS/MS mass spectrometric analysis, in samples 
from each of the individual organs, were compared by running a principal component analysis (PCA) 
analysis. The PCA plots constructed from them showed a clear separation between the control and 
Dex-treated samples for the brain, kidney, heart, and muscle samples (Figure 2A) and skeletal muscles and 
liver (Figure 2B). 
 
 
Figure 2. (A) Principal component analysis (PCA) plot of brain, heart, and kidney tissue samples using the 
protein expression dataset. Shown are the brain (orange, blue), heart (orange, green), and kidney (violet, 
purple) tissues between Dex-treated and control rats, respectively. (B) PCA plot of liver (blue, purple) and 
muscle (orange, green) tissues between Dex-treated and control rats, respectively. The separation seen 
between the treated and the control groups in each tissue sample represents the biological differences due 
to the prolonged Dex treatment. The letters in grey color in the background represent the accession 
numbers of all the implicated proteins in the analysis. (Data were generated using Progenesis QI for 
proteomics (ProgenesisQIfp version 2.0.5387, Nonlinear Dynamics/Waters.). 
The separation between the Dex-treated and control samples in different tissues was apparent in all 
the morphologically altered organs, where the cutoff values to filter these proteins were p-values < 0.05, 
and fold change > 1.5. The number of relatively expressed proteins identified between the Dex-treated 
group compared to the control in the five different organs and the proteins in common between them are 
depicted in the Venn diagram (Table 1, Figure 3). 
Figure 2. (A) Principal component analysis (PCA) plot of brain, heart, and kidney tissue samples
using the protein expression dataset. Shown are the brain (orange, blue), heart (orange, green), and
kidney (violet, purple) tissues between Dex-treated and control rats, respectively. (B) PCA plot of liver
(blue, purple) and muscle (orange, green) tissues between Dex-treated and control rats, respectively.
The separation seen between the treated and the control groups in each tissue sample represents the
biological differences due to the prolonged Dex treatment. The letters in grey color in the background
represent the accession numbers of all the implicated proteins in the analysis. (Data were generated
using Progenesis QI for proteomics (ProgenesisQIfp version 2.0.5387, Nonlinear Dynamics/Waters.).
The separation between the Dex-treated and control samples in different tissues was apparent in
all the morphologically altered organs, where the cutoff values to filter these proteins were p-values
< 0.05, and fold change > 1.5. The number of relatively expressed proteins identified between the
Dex-treated group compared to the control in the five different organs and the proteins in common
between them are depicted in the Venn diagram (Table 1, Figure 3).
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Table 1. This table shows the identity (gene name) of the proteins found to be overlapping between the different organs. The proteins found in common among
the different organs are marked as: + common in heart, brain, liver; ++ common in heart, brain, kidney; ‡ common in kidney, heart, liver; ‡‡ liver, muscle, brain;
† common in brain, heart, muscle; and †† common in brain, kidney, liver.
Heart Muscle Liver Kidney
Brain
Acot1+
ACOT7
Aldh1a7
AP2A2
AP2M1
ATP2B2
ATP5PF++
ATP6V0A1
CEP83
CES1
CHDH†
CLTRN
CPS1+
CSNK2A1
Cyp2d1/Cyp2d5+
DBI
ECHDC3
EIF2D
EPHX1
GSTZ1+
HEATR6
IDH1
MPC2++
Mug1+
MYL2+
NENF
PAFAH1B2
CTSC
PDIA6
PNP
PYGL+
RAB7A
RALA
RNLS
RPS2
RPS16+
STAMBP
STIP1
STX1A
SYN2
Wasl
ATP5F1B
CHDH†
HPX
MGST1
PRDX6
RIPOR2‡‡
Acot1
AKR1A1
AKR1B1
BCKDHA
CA1
COX5B
CPS1
Cyp2d1/Cyp2d5
GAPDH††
GCSH
GDI1
GSTZ1
HADH
HMGCS1
KHK
LDHB
LRRC8
CLYPLA1
Mug1
MYH6
MYL2
PHYHIPL
PYGL
RIPOR2‡‡
RPS16
SLC25A4
SLC25A5
SUOX
Tpm2
VPS45
ATP5PF++
CAPZB
CORO6
COTL1
CSRP1
GAPDH††
GRN
MCCC1
MPC2++
MYH6
NCALD
RAB3A
RAB3C
SCARB1
UCMA
Heart
CHDH
EZR
NDUFA10
RPSA
Acot1+
ACOX1
Akr1c14
ALDOB
AMACR
ASS1
ATP5PO
BAAT
BHMT2
BIN1
Ces1e
CPS1+
CSRP3
Cyp2d1/Cyp2d5+
EEF1A2
FABP1
FABP3
FBP1
FHL2
Gnmt
Gsta1
GSTA3
GSTM2
GSTZ1+
HMGCS2
HSPA5
MAT1A
Mug1+
MYL2+
NDUFA9
PYGL+
RPS16+
Sult1a1
TKFC
UGT2B15
UPB1
ALDH1B1
ATP5PF
BGN
CDKL3
FABP1‡
GSTM1
GSTM2‡
Hsd3b4
MPC2
THNSL2
TXNRD1
Vamp1
Liver
ABHD17B
ACD
ACTN1
CS
IDH3A
KRT24
PC
RIPOR2‡‡
AHSG
FABP1‡
GSTM2‡
PDHB
PKM
Tpm3
GAPDHS
MYH6
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Figure 3. Organ-specific proteome expression: Venn diagram representation of the differentially expressed 
significant proteins (p ≤ 0.05, 1.5 fold change) identified within the morphologically altered organs from 
Dex-treated and control animals. Number of proteins expressed in common among various organs are 
shown in the intersections. The number of proteins specific for each organ namely the heart (n = 83), kidney 
(n = 12), brain (n = 81), liver (n = 131), and muscle (n = 18). The highest number of overlaps was found to be 
between the heart and brain (n = 42) followed by the heart and liver (n = 39) and the liver and brain (f = 30), 
while only eight proteins were common among the three groups and no proteins were in common between 
the muscle and kidney. The area of the Venn diagram is not representative of the numbers of identified 
proteins. 
Table 1. This table shows the identity (gene name) of the proteins found to be overlapping between the 
different organs. The proteins found in common among the different organs are marked as: + common in 
heart, brain, liver; ++ common in heart, brain, kidney; ‡ common in kidney, heart, liver; ‡‡ liver, muscle, 
brain; † common in brain, heart, muscle; and †† common in brain, kidney, liver. 
Figure 3. Organ-specific proteome expression: Venn diagram representation of the differentially
expressed significant proteins (p ≤ 0.05, 1.5 fold change) identified within the morphologically altered
organs from Dex-treated and control animals. Number of proteins expressed in common among various
organs are shown in the intersections. The number of proteins specific for each organ namely the heart
(n = 83), kidney (n = 12), brain (n = 81), liver (n = 131), and muscle (n = 18). The highest number of
overlaps was found to be between the heart and brain (n = 42) followed by the heart and liver (n = 39)
and the liver and brain (f = 30), while only eight proteins were common among the three groups and
no proteins were in common between the muscle and kidney. The area of the Venn diagram is not
representative of the numbers of identified proteins.
2.2. Mass Spectromeric Protein Identification and Analyses
A label-free MS-based tool was used for quantitative and comparative expression analysis
of the protein changes between the prolonged Dex-treated versus control rats in different organs.
The proteomic analysis revealed 190 significantly differentially expressed proteins (ANOVA test,
p < 0.05, >1.5 fold change (FC)) in the brain (91 up and 99 down), 193 proteins in the heart (78 up and
115 down), 39 proteins in the muscle (30 up and 9 down), 230 protein in the liver (128 up and 102 down),
and 53 proteins in the kidney (38 up and 15 down) in the Dex-treated versus control rats. A list of
all the differentially expressed proteins identified in the different organs with their fold changes is
shown in Supplementary Materials Table S1. The detailed table of the list of proteins with their mass
spectrometry data, mean abundances, and standard deviations can be accessed at the peptide atlas
database [21].
We further analyzed the identified proteins statistically using the t-test and by applying false
discovery rate (FDR)-corrected p-values (y-axis), and fold change (FC) (x-axis) analyses were evaluated
and visualized graphically using the volcano plot. The significant features shown in the volcano plot in
the brain (Figure 4A), heart (Figure 4B), liver (Figure 4C), muscle (Figure 4C), and kidney (Figure 4D)
are the ones that passed the FC and FDR-corrected p-value thresholds of 1.5 and 0.05, respectively.
Proteins shown in pink dots in the upper right and left corners of the plot, respectively, represent
significantlydownregulated or upregulated features upon Dex treatment.
The differentially abundant protein sets identified from the brain, heart, muscle, liver, and kidney
tissues were next uploaded and investigated further using the ingenuity pathway analysis (IPA)
software to determine their functional and biological roles.
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2.2.1. Gene Ontology and Functional Analysis of the Identified Proteins in the Five Organs
Gene ontology annotation and functional analysis of the identified proteins were carried out to
ascertain the different types of identified proteins and major biochemical functions associated with them
that were affected after prolonged Dex treatment. The significantly differentially abundant proteins in
the different rat organs were classified according to their function and location. Proteins significantly
enriched in the brain, heart, muscle, liver, and kidney were classified by the IPA as enzymes (n = 82,
104, 21, 126, 20, respectively), ion channel proteins (n = 4, 1, 1, 3, 0, respectively), kinase (n = 9, 7, 0, 8,
2, respectively), transcription and translation regulators (n = 8, 5, 2, 11, 0, respectively), transporter
(n = 22, 19, 3, 20, 7, respectively), and others (n = 65, 57, 12, 62, 24, respectively). In terms of the location
of the identified proteins in the brain, heart, muscle, liver, and kidney, in that order, they were localised
by the IPA, mainly to the cytoplasm (n = 120, 137,27, 181, 32, respectively), plasma membrane (n = 22,
22,4, 15, 6, respectively), nucleus (n = 21, 19, 1, 6, 2, respectively), extracellular space (n = 16, 10, 2, 12, 9,
respectively), and others (n = 6, 5, 5, 6, 4, respectively).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 2 of 25 
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Figure 4. Plots showing the statistically significant expressed proteins in brain tissue (A), heart (B),
skeletal muscle (C), liver (D), and kidney (E) after prolonged Dex administration false discovery rate
(FDR-corrected p-value < 0.05), and fold change FC > 1.5 were visualized in each volcano plot in the
left and right corners as down- and upregulated, respectively, in the Dex-treated rats.
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The molecular and functional processes affected by Dex treatment revealed the involvement
of different biological processes within these organs. The two top significantly altered molecular
functions (and number of associated proteins) that were identified in the brain were related to cellular
compromise (n = 42) and molecular transport (n = 65); in the heart and liver they were related to amino
acid metabolism (n = 21, 26, respectively) and small molecule biochemistry (n = 86, 103, respectively).
In the muscle, these processes related to vitamin and mineral metabolism (n = 5) and energy production
(n = 5), and in the kidney, they were related to drug metabolism (n = 5) and molecular transport
(n = 16) (Supplementary Materials Table S3). Dex treatment was also found to affect and regulate
the canonical pathways differently in each organ. The top canonical pathway affected in the brain
post-prolonged Dex treatment was found to be the leucine degradation pathway, while that in the
muscle was glutathione redox reactions. The top canonical function affected in the kidney, liver,
and heart was found to be LPS/IL-1-mediated inhibition of LXR and RXR function. This is in line with
previous studies that demonstrated glucocorticoid-mediated regulation of this pathway to affect lipid
metabolism [22] (Supplementary Materials Table S4).
2.2.2. Network and Pathway Analysis
The protein expression datasets identified in the different organs were uploaded into the IPA
software to identify the pathways related to these proteins. The networks generated by this approach
are preferentially enriched for proteins with the most extensive and specific interactions using the
ingenuity knowledge base. The interacting proteins are represented as nodes, the direct biological
relationship among two nodes as a line and an indirect relationship as a hashed line.
Network analysis of the differentially expressed proteins between the Dex-treated and control rats
in the brain identified the pathway with the highest score, related to cell morphology, nervous system
development, and function and neurological disease (score = 38) (Figure 5A). The central node of the
identified pathway was mitogen–activated protein (MAP) kinase whose activity was suggested to be
reduced in the Dex-controlled rats versus controls. In the heart tissue, the pathway identified was
related to cellular development, cellular function and maintenance, and connective tissue development
and function (score = 43) (Figure 5B) with the protein kinase B (Akt) as its central node. The pathway
identified in the muscle with the highest score related to nucleic acid metabolism, small molecule
biochemistry, and vitamins and mineral metabolism (score = 50) (Figure 5C), and identified janus
kinases (Jnk), protein kinase C, insulin, and extracellular-signal regulated kinases ERK as the central
nodes involved in the regulation of Dex action. The highest scoring network pathway identified in
the rat liver related to lipid metabolism, small molecular biochemistry, and nucleic acid metabolism
(score = 41) (Figure 5D), and identified Akt and phosphoinositide 3-kinase (PI3 kinase) as the central
nodes. In the kidney, the pathway identified with the highest score was related to drug metabolism,
organism injury, and abnormalities and renal damage (score = 41) (Figure 5E), and showed Jnk, ERK,
insulin, nuclear factor kappa-light-chain-enhancer of activated B cells NFkB, and p38 MAP kinases as
the central nodes.
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control rats identified by the IPA (ingenuity pathway analysis). (A) Brain network pathway 
converged on the central signaling pathway involving extracellular signal–regulated kinases 
(ERK1/2), janus kinase (Jnk), and Akt. The network with the highest score related to cell morphology, 
nervous system development, and function and neurological disease (score = 38). (B) Heart network 
pathway identified the involvement of Akt and phosphoinositide 3-kinase (PI3 kinase) signaling 
pathways. The network with the highest score related to cellular development, cellular function and 
maintenance, and connective tissue development and function (score = 43). (C) Skeletal muscle 
network pathway identified with the highest scoring network (score = 50) related to nucleic acid 
metabolism, small molecule biochemistry, and vitamins and mineral metabolism. (D) Liver network 
Figure 5. Network analysis of the diff rentially ex r ssed proteins between the Dex-treated and
control rats identified by the IPA (ingenuity pathway analysis). (A) Brain network pathway converged
on the central signaling pathway involving ex racellular signal– gulated kinases (ERK1/2), janus
kinase (Jnk), and Akt. The network with the highest score related to cell morphology, nervous
system development, and function and neurological disease (score = 38). (B) Heart network pathway
identified the involvement of Akt and phosphoinositide 3-kinase (PI3 kinase) signaling pathways.
The network with the highest score related to cellular development, cellular function and maintenance,
and connective tissue development and function (score = 43). (C) Skeletal muscle network pathway
identified with the highest scoring network (score = 50) related to nucleic acid metabolism, small
molecule biochemistry, and vitamins and mineral metabolism. (D) Liver network pathway was
identified with the highest scoring network (score = 41) related to lipid metabolism, small molecule
biochemistry, and nucleic acid metabolism. (E) Kidney network pathway was identified with the
highest scoring network (score = 41) related to drug metabolism, organism injury, and abnormalities
and renal damage. Nodes in green and red correspond to down- and upregulated proteins, respectively.
Non-colored nodes were proposed by IPA and suggest potential targets functionally coordinated with
the differential proteins. Solid lines indicate direct molecular interactions and dashed lines represent
indirect relationships.
3. Discussion
The synthetic GC derivative Dex mimics the actions of natural glucocorticosteroids and affects
nearly all the tissues and physiological processes that are regulated by them. The effectiveness of
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long-term therapy with Dex is limited due to the serious side effects that negate its clinical benefits.
These effects, for the most part, are mediated via the genomic and non-genomic signaling pathways [23]
through interactions with the pleiotropic GR, which is expressed in nearly every cell of the body [24].
The GRs have variable cell-type-specific effects on proliferation, differentiation, and apoptosis and
are maintained as an inactive cytoplasmic complex with cofactors, such as heat-shock proteins and
immunophilins [25]. A holistic understanding of the diverse cellular responses and heterogeneity
in GR signaling in diseased tissues will aid in understanding the side effects that arise due to their
pharmacological use. Numerous studies have been undertaken in the past to elucidate the mechanism
of developments of Dex-related adverse reactions. However, even with this bulk of literature, the exact
mechanism of the overall systemic Dex action has not yet been elucidated.
A majority of the previous studies used a targeted approach focusing on either a single pathway
or a target organ to identify the mechanisms of development of adverse effects. In the present study,
we used an untargetted LC-MS/MS quantitative proteomic approach to analyze the proteome of the
morphologically altered individual organs (i.e., brain, heart, muscle, liver, and kidney) between the
controlled and the Dex-treated SD rat model, after development of side effects. The Dex-treated male
rats were found to suffer from a severe reduction in weight gain, high blood sugar, essential changes in
serum lipid, and reduction in total serum alkaline phosphatase (ALP) [10]. The animal model provided
us with an effective method for profiling the differences in protein expression within each tissue and
also among them to allow identification of organ-specific Dex-related adverse effects [26].
3.1. Proteomic Profiling of the Major Tissues Affected by Dex Treatment
The proteomic profiling of the individual protein datasets, from the five different morphologically
altered organs, identified the involvement of not only different proteins but also the number of proteins.
The highest number of significantly altered proteins, between the Dex-treated and control rats, were
found in the dataset of the liver (n = 230) followed by the heart (n = 193), brain (n = 190), kidney
(n = 53), and the muscle (n = 39).
3.1.1. Proteins Related to the Reduced Brain Size after Dex Treatment
The action of Dex and glucocorticoids are known to affect the brain and the central nervous system,
causing psychiatric and cognitive–behavioral and memory disturbances [27]. In their proteomic study,
Feldman et al. [28] demonstrated that increased corticosterone levels mimic chronic stress and were
associated with hippocampal atrophy and cognitive dysfunction. We found that the pathways in the rat
brain related to cell morphology, nervous system development and function, and neurological disease
with the central nodes focused around tau protein, Akt, and PI3K signaling pathways, and heat-shock
proteins 70 and 90 (Figure 5A). Our findings are in line with Skynner et al. [29] who also showed a
significant alteration in the morphology of the hippocampus and cerebral cortex in relation to cell
morphology, and cellular assembly and organization. The decrease in brain weight seen in our study
was similar to the findings of Devries and Bentson et al. [30,31], who also showed an increase in brain
atrophy in chronically corticosteroid-treated patients. The main pathway that we could identify in the
rats’ brain tissue was related to Akt signaling with decreased abundance of microtubule-associated
tau protein (Mapt) [32]. The cytoskeletal Tau protein is a crucial regulator of neuronal malfunction
found in stress-driven hippocampal pathology. Its decrease or absence blocks the stress-evoked
hippocampal synaptic signaling and morpho-functional damages related to both neuronal structure
and connectivity as well as subsequent behavioral deficits [33]. The decrease in the levels of Mapt
was also shown by Haynes et al. [34], who showed that systemic administration of dexamethasone in
rats caused a dose–dependent decrease in immunoreactivity to Mapt and activation of the microglia.
The proteomic changes in the brain were confirmed by the serum metabolomic changes identified in
our previous study that showed an increase in levels of kynurenine, 3-hydroxy-kenurenine, tryptophan,
and secondarily serotonin that inhibited extracellular dopamine and glutamate release [35].
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3.1.2. Proteins Related to Decreased Heart Size after Dex Treatment
Exogenous glucocorticoids such as Dex influence normal development and function of the heart
and are known to have both positive and negative effects on it, although their direct role on signaling
pathways remains unknown [36]. Prolonged Dex treatment leads to cardiac hypertrophy leading to the
development of hypertension and insulin resistance. In their study, Ren et al. [37] found an increase in
the hypertrophic markers that included an atrial natriuretic factor, β-myosin heavy chain and skeletal
muscle α-actin. In growing animals, administration of Dex also causes decreased somatic growth and
an increase in atherosclerotic events due to the presence of dyslipidemia [38]. The Dex-treated rats’
heart proteomes showed an increase in the levels of the enzyme hydroxysteroid 11-beta dehydrogenase
1(HSD11B1), which is known to augment GC action and increase the adverse effects of the drug, leading
to increased insulin resistance, dyslipidemia, and hypertension [39]. The highest scoring network in
the heart tissue between the Dex-treated and controlled rats related to pathways that were involved
in cellular development, cellular function and maintenance, and connective tissue development and
function. The central nodes were related to Akt and protein kinase C signaling pathways and also
involved the heat-shock proteins 5 and 90 (Figure 5B). The heat-shock proteins functionally bind the
GR to keep it in the normal inactive state and are released following Dex treatment for the translocation
of the hormone-receptor complex into the nucleus for gene expression [23]. Involvement of the Akt
signaling pathway in the heart tissue indicates the involvement of non-genomic actions of Dex in the
development of side effects in the heart characterized by its reduced size compared to the controls.
This can be related to the repressive effect of Dex on the proteins involved in the cell cycle [40] leading to
suppression of the growth of cardiomyocytes [41] and a decrease in heart weight due to the inhibition
of myocyte mitotic activity [30].
3.1.3. Proteins Related to Muscle Atrophy after Dex Treatment
Dexamethasone is a well-known inducer of muscle atrophy and myopathy [42] and is considered
one of the causes for increased weight loss [43]. Prolonged use of the glucocorticoid is also known
to have a catabolic and atrophic effect on skeletal muscle through increased gluconeogenesis [44],
interfering with insulin-like growth factor-1 signaling [45] and influencing Akt1 signaling [46], resulting
in increased degradation of muscle proteins. We found that the proteins identified in the muscle
between the Dex-treated rats’ and controls’ datasets generated a network pathway which related to
nucleic acid metabolism, small molecule biochemistry and vitamins, and mineral metabolism. It was
interesting to note that the central nodes of the network were involved in the regulation of Akt, ERK,
Jnk, AMPK, and the insulin signaling pathways (Figure 5C). Involvement of these pathways shows
that Dex influences glucose metabolism, causes decreased protein synthesis and increased proteolysis,
and causes morphological and functional damage to the muscle precursor cells such as the myoblast
and also induces apoptosis. Involvement of AMPK signaling pathway, which acts on glucose utilization
by increasing the expression of Glut4, and ERK signaling pathway also points to the important role of
Dex in the regulation of insulin signals in muscle cells that have developed endoplasmic reticulum
stress. These perturbations all relate to the development of insulin resistance myopathy observed
post-Dex treatment [47]. Our findings are further confirmed with the distinct amino acid profile
determined through our previous metabolomics study that showed decreased protein synthesis and an
increased proteolysis characterized by an increase in the levels of amino acid glutamine by promoting
protein catabolism.
3.1.4. Proteins Altered in the Liver After Dex Treatment
In the liver, treatment with Dex changes the expression of the different hepatic enzymes,
and increases the activity of key enzymes of the lipid metabolism, gluconeogenic pathway, the amino
acids metabolism, the urea cycle [48], and the cytochrome p450 system which regulate many
xenobiotic-metabolizing enzymes. In addition to these molecular effects, it also leads to morphological
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changes such as hepatomegaly and fatty liver [22,49] due to the hepatocyte hypertrophy from increased
glycogen storage or fat accumulation [50]. A recent study by Ayyar et al. [51] studied the proteome-wide
effects of methylprednisolone and its responses in the rat liver by using a functional pharmacoproteomic
approach. They identified differential regulation of proteins related to various aspects of energy
metabolism, amino acid metabolism, carbohydrate metabolism, lipid/fatty acid metabolism, and the
Krebs cycle. The liver protein dataset identified in our study also pointed to a similar increase in
the proteins involved in lipid metabolism, and gluconeogenic and urea cycle pathways. The highest
scoring network pathway, identified using the IPA, related to lipid metabolism, small molecular
biochemistry, and the nucleic acid metabolism pathway. The central nodes of the network were found
to focus around an increase in the cytochrome P450 reductase system and involved the Akt and PI3
kinase signaling pathways (Figure 5D). Involvement of these signaling pathways has been implicated
in a number of physiological cellular responses including survival, proliferation, protein synthesis,
migration, vesicular trafficking, and increased mitochondrial respiration, as well as in pathogenesis
of multiple diseases ranging from chronic inflammation to cancer [52]. These findings are also in
line with the metabolomics study that found an increase in the levels of the acylcarnitines indicating
an increased lipolytic state and an increase in gluconeogenic amino acids indicating an increase in
gluconeogenesis [53].
3.1.5. Proteins Altered in the Kidney After Dex Treatment
Dexamethasone is known to exert a direct action on the kidney on the renal tubular cells as
well as the podocytes. It increases the renal vasodilatory effect, diuresis, the glomerular filtration
rate, and the renal plasma flow [54]. The actions of Dex on the kidney are attributed to its inhibition
of NFκB, which abrogates the inflammatory effects on both proteome and metabolome [55], and by
increasing levels of angiotensin II and fibronectin which have been suggested to contribute to renal
tubular fibrosis [56]. The protein dataset identified from the kidney in our study, when entered into the
pathway analysis, identified with the highest score the network related to drug metabolism, organismal
injury and abnormalities, and renal damage (Figure 5E). The central nodes of the network identified
the involvement of insulin, ERK 12 , p38 MAPK, Jnk, and NFκB signaling pathways highlighting
the involvement and cross-talk among these related nodes. The coordinated stimulation of NFkB
and Jnk cascades by inflammatory cytokines demonstrated by an increase in interleukins, IL 1 and
IL18, in our dataset points towards alterations in proteins involved in glucose metabolism, apoptosis,
and inflammation in the kidney, post-Dex treatment [57]. Involvement of these signaling pathways
indicates an increase in Dex-mediated genomic regulation within the rat kidney that may lead to the
development of side effects [3].
We found that among all five organs, the single signaling pathway that emerged as the point of
commonality for the action of dexamethasone involved the Akt signaling pathway. This indicates that,
more than the genomic actions, the development of side effects is due to the non-genomic actions of
Dex mediated vis-a-vis the cytosolic GR. The GR, thus, mediates both the well-known genomic actions
of the corticosteroid and is also involved in its much rapid non-genomic effects due the to complex
interactions with various signaling processes [3].
3.1.6. Proteins Altered in All Organs Treated with Dex
The proteins identified in the different organs between the Dex-treated and control rats were
grouped together, and an additional bioinformatics analysis was carried out to get an overall view of
the general effect of prolonged Dex treatment. The network analysis of all the differentially expressed
proteins identified the network related to endocrine system development and function and drug
metabolism and biochemistry, with a score of 83 (Figure S1). The highlighting of this pathway is
in line with the different adverse effects that were previously seen with prolonged Dex use on the
neuroendocrine, cardiovascular, and renal systems [58].
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3.2. Comparison Amongst the Morhologically Altered Organs after Dex Treatment
The datasets were explored to identify if the proteomes of the tissues under study had proteins
in common among them. We found that the proteomic profiles of these tissues after prolonged Dex
treatment differed substantially from one another (Figure 2). Among all organs, the highest number
of proteins in common was found between the heart and brain (n = 49), followed by the heart and
liver (n = 39), and lastly the liver and brain (n = 30). On further probing, we found that eight proteins
were in common between these three tissues (Figure 3 and Table 1). The other organs showed less
similarity with regards to the differentially abundant proteins (Figure 3). What was intriguing was that
we found no proteins in common between the muscle and the kidney datasets, which goes to show
that the mechanism of action of Dex in these two organs is different from the others. The top canonical
pathways affected by prolonged Dex treatment were different for all the organs while those pathways
found in common between the organs had varied involvement. The liver, kidney, and heart protein
datasets showed the LPS/IL-1-mediated inhibition of RXR function (10.4%, 3.7%, 6.6%, respectively)
in common, the kidney and heart datasets had glutathione-mediated detoxification (10% and 25%,
respectively), while the muscle and brain showed the involvement of glutathione redox reaction (8.7%
and 22.7%, respectively). These findings demonstrate the differences in the degrees of involvement of
the metabolic pathways in different organs by Dex probably due to the differences in the glucocorticoid
receptor isoforms and their activity.
A direct comparison of our results to other proteomic studies was difficult due to the differences
in experimental techniques, duration, and type of treatments used, although similar results have been
seen [18,29,51,59]. Our present study has, for the first time, demonstrated the effects of the treatment
with Dex simultaneously on the major organ targets. Through this study, we have carried out a
proteome mapping of each organ and demonstrated the immense complexity and differential actions
of Dex within these different tissues, in essence, evaluating the drug’s effects.
4. Materials and Methods
4.1. Ethical Considerations
Prior to implementation, all procedures and protocols for the animal studies were reviewed and
approved by the Animal Care and Use Committee (ACUC) at King Faisal Specialist Hospital and
Research Center (KFSHRC) (approval number RAC2150016). The animal model details were published
elsewhere [10], where Sprague–Dawley (SD) rats were housed in the animal facility of the Department
of Comparative Medicine at KFSHRC (Riyadh, Saudi Arabia).
4.2. Experimental Design
A standard protocol of housing the study’s male SD rats was adopted, where the age of the
rats ranged from 6 to 8 weeks (weight: 200–250 g). These rats were housed at the Department of
Comparative Medicine under standard environmental conditions: temperature (20–24 ◦C), humidity
(45–50%), and 12 h/12 h light/dark cycle with free access to food and water. Rats were randomly
separated into two groups; Dex (n = 10) and control (n = 10) group. The Dex group was injected
intramuscularly with 2.5 mg/kg twice a week for 14 weeks with Dex while the control with normal
saline. This method was developed earlier by Li et al. [60] and Huang et al. [61] who considered giving
equivalent long-term treatment of the drug for a chronic disease to develop the serious side effects
of the drug. The clinical phenotype, anesthesia protocol, and the routine blood work analysis were
monitored during this study and detailed previously [10]. After 14 weeks post-treatment, the animals
were sacrificed (n = 5/group) and their major organs (brain, heart, muscle, liver, and kidney) collected,
snap-frozen in liquid nitrogen, and then stored at −80 ◦C for further proteomics analysis. The other
5 animals included in the study were used for radiological studies as reported elsewhere [10].
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4.3. Chemicals and Reagents
The dexamethasone phosphate drug, analytical solvents, and other standard chemicals for
proteomics were obtained from Sigma–Aldrich (St. Louis, Missouri, USA). The reagents for routine
chemistry analyses were purchased from Roche (Kaiseraugst, Switzerland).
4.4. Proteomics
4.4.1. Sample Preparation for Label-Free Protein In-Solution Digestion
Homogenized tissue lysates were prepared from rat brain, heart, muscle, liver, and kidney tissues
and were subjected to proteomic analysis (Figure 1). For each sample, 100 µg total protein extract was
subjected to in-solution tryptic digestion, as previously described [62] Briefly, proteins were denatured
in 0.1% RapiGest SF (Waters, Manchester, UK) at 80 ◦C for 15 minutes, reduced in 10 mM Dithiothreitol
(DTT) at 60 ◦C for 30 min, and alkylated in 10 mM Iodoacetamide (IAA) (1.0 µL IAA/10 µL) in the dark
for 40 min at room temperature. Samples were trypsin-digested overnight at 37 ◦C and the RapiGest
reaction quenched with 12 M HCl. All samples were diluted with aqueous 0.1% formic acid before to
achieve concentrations of 1 µg/µL before LC-MS/MS analysis.
4.4.2. Protein Identification by LC-MSE SynaptG2 Platform
We undertook label-free quantitative expression profiling using 1-dimensional nanoACQUITY
liquid chromatography combined with tandem mass spectrometry on a Synapt G2 HDMS instrument
(Waters Scientific, Berkshire, UK). The electrospray ionization (ESI) mass spectrometry analyses were
optimized and all acquisitions were carried out on a Trizaic Nano source (Waters) ionization in the
positive ion mode nanoESI as previously described [62]. Briefly, the Mass Lynx IntelliStart was used to
adjust for optimal instrument parameters including the following: detectors were set-up using 2 ng/µL
leucine enkephalin (556.277 Da) and lock mass set-up and mass (m/z) calibration were achieved on a
separate infusion line of 500 fmol (Glu) 1-fibrinopeptide B (GluFib, 785.8426 Da, capillary voltage 3 kV,
sample cone 50 V, and extraction cone 5 V). Other parameters included source temperature 85 ◦C, cone
gas 8 L/h, nano flow gas 0.5 bar, and purge gas 600 L/h.
Equal amounts of protein digest (3 µg) was loaded on a column (AcquityTrizaic Nano tile HSS T3
1.8 µm, 85 µm × 100 µm, Waters) and samples were processed using the Acquity sample manager with
mobile phase comprising of A1 (99% water/1% acetonitrile/0.1% formic acid) and B1 (100% acetonitrile
+ 0.1% formic acid) with sample flow rate of 1 µL/min. Data independent acquisition (MSE)/iron
mobility separation analyses were performed and data were acquired over a range of m/z 50–2000 Da
with a scan time of 0.9 s and incremental transfer collision energy 20–50 V with a total acquisition
time of 120 min. Data were acquired using the Mass Lynx program (version. 4.1, SCN833; Waters)
operated in resolution and positive polarity modes and each sample was analyzed in triplicate runs
(as a measure of reproducibility) and all samples were analyzed in the same batch run.
All automated data processing and database searching was done using Progenesis QI for proteomics
(ProgenesisQIfp version 2.0.5387, Nonlinear Dynamics/Waters, London, UK). The generated peptide
masses were searched against the non-redundant species-specific protein sequence in the Uniprot
database [63].
4.5. Data Analysis and Informatics
Progenesis QI for proteomics (ProgenesisQIfp version 2.0.5387) was used to process all Mass Lynx
generated raw data and database search for protein identification. Each run in the experiment was
represented as an ion intensity map, including the m/z and retention time, aligned and propagated for
peak picking and peptide abundance measurements. The generated list of peptide ions for identification
was subjected to a static database for searching using a search engine in Progenesis and the list of
identified protein datasets were reviewed using multivariate statistical analyses.
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A rat-specific database containing thousands of reviewed entries from Uniprot was created prior
to searching as previously described [62,64]. The following criteria were used for the search: one
missed cleavage, maximum protein mass 1000 kDa, trypsin, carbamidomethyl C fixed, and oxidation
M variable modifications. Normalized label-free quantification was achieved and subjected to
statistical analyses to plot principal component analysis (PCA) against data split into multiple groups.
The data were filtered to show only statistically (ANOVA) significantly altered proteins (p ≤ 0.05) with
≥3 peptides identified, and a fold change of more than 1.5 was considered as the significant minimum
threshold. Additionally “Hi3” absolute quantification was performed using alcohol dehydrogenase
(ADH P00330) as an internal standard to give an absolute amount of each identified protein (Waters) as
previously described [65]. These features are available as incorporated into ProgenesisQIfp (Nonlinear
Dynamics/Waters, London, UK).
The analysis features available in ProgenesisQIfp (Nonlinear Dynamics/Waters) allows data to be
filtered to show only statistically (ANOVA) significantly altered proteins as well as fold change in the
levels of protein expression among sample pairs being compared. In this instance, we chose the level
of significance at the 95% confidence interval, i.e., p ≤ 0.05, while we chose a fold change of more than
1.5 as the significant minimum threshold. Each sample was run in triplicates and the program took the
average of the three runs and used the value in the expression ration of one protein among samples
being compared.
The proteomics expression profile was analyzed using MetaboAnalyst version 3.0 (McGill
University, Montreal, Canada) [66]. The protein expression raw data among the study groups for
each organ were uploaded to the software. The datasets were normalized to their sample total
median for the specific organ set to ensure all samples were normally distributed. To visualize the
proteomics differences among the study groups and make individual features more comparable,
data were log-transformed and Pareto scaled, respectively. As the data were Gaussian distributed,
the unpaired two-tailed Student’s t-test was used for binary comparison between the different study
groups. Proteins were considered significant if they had an FDR-corrected p-value < 0.05 with 1.5 cut
of fold change and visualized in a volcano plot.
4.6. Bioinformatics Analysis of Proteins in the Tissues and Network Pathway Analysis:
To understand the role of the identified proteins and interrogate the intracellular signaling
pathways affected by alterations in these cellular proteins, gene ontology annotations were ascribed
and network pathway analysis for the respective protein expression datasets for each organ were
carried out. The quantitative protein data were imported into IPA software (Ingenuity® Systems, [67])
for identification of the protein–protein interactions. This software also helps to determine the functions
and pathways most strongly associated with a protein list by overlaying experimental expression
data on networks constructed from published interactions. The identified networks help to infer
the identity of upstream regulatory molecules and the associated mechanisms to provide biological
insight to the observed experimental expression changes seen by the proteomics experiment. A score
greater than three (p ≤ 0.001) indicates a greater than 99.9% confidence that a protein network was not
generated by chance alone [68]. The score does not indicate the quality or significance of the network,
it simply calculates the approximate “fit” between the network and the focus protein from the input
dataset. The networks generated by this approach are preferentially enriched for proteins with the
most extensive and specific interactions. The interacting proteins are represented as nodes, and the
biological relationship between two nodes is represented as a line. Although powerful, the biological
significance of the network(s) identified by this approach must ultimately be verified by experiment.
5. Conclusions
Our study is the first to use an untargeted LC-MSMS mass spectrometric approach to carry out
a simultaneous comprehensive organ-specific proteomic profiling in SD rats after prolonged Dex
treatment. The proteome of the five different organs was identified, explored, and systematically
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mapped to diverse molecular network pathways that were functionally influenced by the treatment.
Identification of these pathways will help in better understanding the protein–protein interactions,
their dynamics, and the proteomic and molecular signatures of the drug’s effects and side effects within
them. These proteins can be developed into markers with potential use in monitoring for adverse
effects and developing strategies towards preventing them.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/13/3122/
s1. Table S1. List of differentially expressed significant proteins, with the fold change and p-values, identified in
different organs between Dex-treated versus control SD rats using a label-free quantitative LC-MS/MS approach.
Table S2. Table showing the abbreviations (gene name) and full name for all proteins mentioned in Table 1.
Table S3: Table showing the top three molecular and cellular functional categories significantly altered in each
organ after long-term Dex treatment with their p-value range, number of molecules involved, and the gene names
of the involved proteins. Table S4: Table showing the IPA identified canonical pathways altered by Dex treatment.
Figure S1. Network analysis of all the differentially expressed proteins identified in the different organs between
the Dex-treated and control rats. The network identifies an integrated pathway that demonstrates the overall effect
of prolonged dexamethasone in the treatment versus the control rats with the network related to drug metabolism,
endocrine system development and function, and biochemistry with the score of 83.
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